Report Overview

The Indian Polycystic Ovarian Syndrome Treatment Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Polycystic Ovary Syndrome (PCOS) is a medical condition where the women of reproductive age suffer from hormonal disorders. This is due to an increase in levels of male hormones in the body which leads to an irregular menstrual cycle. Women experience symptoms such as irregular menstrual cycle, increase in facial hair growth, acne, thinning hair or hair loss on the scalp, weight gain, darkening of skin and others. Polycystic Ovary Syndrome (PCOS) is caused due to high levels of androgens, excess insulin, low-grade inflammation, cysts in the ovaries, and genetic disorders. The polycystic ovarian syndrome market is expected to witness tremendous growth owing to the rising prevalence of polycystic ovarian syndrome. According to the Centers for Disease Control and Prevention, approximately XX Billion women of reproductive age suffer from the polycystic ovarian syndrome in India.



Market Drivers

The increasing burden of PCOS and the unavailability of targeted therapy for PCOS in the market create a need to develop treatment therapies. The players in the market are currently focusing on the unmet need of the market and on strengthening their pipelines to leverage the opportunities; the commercialization of these robust pipelines is expected to propel market growth. Other key factors such as the growing obesity among women, rising prevalence of diabetes, increasing hormonal disorders in women, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, and others are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of the polycystic ovarian syndrome. Such factors contribute to polycystic ovarian syndrome among women. The factors such as side effects associated with drugs such as weight gain, cardiovascular risks, increase insulin resistance, abnormal glucose tolerance, and thromboembolic eventsare expected to restrict the market growth during the forecast period.